ArticleEmerging microbes & infections2021
Colistin-phage combinations decrease antibiotic resistance in
Article in Emerging microbes & infections, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 104 citations in OpenAlex.
- Engineering the probioticSynthetic and systems biotechnology · 2026Article
- Modeling Phage-Antibiotic Synergy, Innate Immunity, and Phage Resistance in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- The Therapeutic Potential of Phages in Multi-Drug Resistance Infections and Future Directions.Viruses · 2026Review
- Personalized Phage Therapy in an ICU Patient with Polymicrobial Pulmonary Infections: a case from a single-arm trial.Nature communications · 2026Article
- The Single Amino Acid Substitution in WcaJ(Ser332Leu) Promotes Hypervirulent Klebsiella Pneumoniae Resistant to Bacteriophage and Virulence Attenuated.Probiotics and antimicrobial proteins · 2026Article
- Article
- Bacteriophages hijack 2',3'-cNMPs to enhance transposase-mediated phage DNA integration inScience advances · 2026Article
- Synergy antibacterial effects of lytic phage vB_AbaA_LLY and levofloxacin against KL2 and KL160 Acinetobacter baumannii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Synergistic strategies to rescue the last-resort antibiotic colistin.Archives of microbiology · 2026Review
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The therapeutic potential of phage pT2784 against ST40-KL47 typeMicrobiology spectrum · 2026Article
- Combinations of colistin and bacteriocins prevent the selection of colistin resistance in Acinetobacter baumannii.Communications biology · 2026Article
- Review
- Bacterial defense mechanisms against bacteriophages: an evolutionary arms race.Archives of microbiology · 2026Review
- Article
- Advances in phage therapy forFrontiers in microbiology · 2026Review
- A bacteriophage genus infects carbapenem resistantiScience · 2025Article
- Phage resistance of Bordetella avium due to an altered cell wall results in increased susceptibility to the polypeptide antibiotics colistin and polymyxin B.Scientific reports · 2025Article
- Effects of bacteriophages on gut microbiome functionality.Gut microbes · 2025Review
- Infection and resistance mechanisms of phage vB_VpM-PP270 iniScience · 2025Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant bacterial infections are becoming increasingly common, with only few last-resort antibiotics such as colistin available for clinical therapy. An alternative therapeutic strategy gaining momentum is phage therapy, which has the advantage of not being affected by bacterial resistance to antibiotics. However, a major challenge in phage therapy is the rapid emergence of phage-resistant bacteria. In this work, our main aim was to understand the mechanisms of phage-resistance used by the top priority pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.